Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04856884 + Axitinib in mRCC
NCT01441414Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2011
- Primary completion
- Mar 2014
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of PF-04856884 in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Non-serious Adverse Events at 4 months, Number of Participants With Serious Adverse Events at 4 months and 1 more. Started Nov 2011; status: terminated.
02
Drugs
PF-04856884
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT01441414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01441414.